CHA
AVDL

Carmichael Hill & Associates’s Avadel Pharmaceuticals AVDL Stock Holding History

Carmichael Hill & Associates’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Hold
0
– -$28.2K – 767
2023
Q4 		– Hold
0
– – – 426
2023
Q3 		– Hold
0
– – – 462
2023
Q2 		– Hold
0
– – – 399
2022
Q1 		– Sell
-2,000
Closed -$16K – 791
2021
Q4 		$16K Sell
2,000
-1,000
-33% -$9.14K 0.01% 544
2021
Q3 		$29K Hold
3,000
– – 0.01% 463
2021
Q2 		$20K Hold
3,000
– – 0.01% 514
2021
Q1 		$27K Buy
+3,000
New +$24.3K 0.01% 452

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return

Carmichael Hill & Associates's AVDL Position: Q3 2024 in Review

Carmichael Hill & Associates held its Avadel Pharmaceuticals (AVDL) position steady in Q3 2024 at 21,000 shares worth $275K. The position accounts for 0.1% of the portfolio, ranked #156.

Carmichael Hill & Associates first reported a position in AVDL in Q4 2019 and has held it in 20 quarters since. The position peaked at $355K in Q1 2024. 176 funds tracked by Wall St. Rank hold AVDL as of Q3 2024.

  • Carmichael Hill & Associates held 21,000 shares of Avadel Pharmaceuticals worth $275K as of Q3 2024.
  • Carmichael Hill & Associates left its Avadel Pharmaceuticals share count unchanged in Q3 2024.
  • Avadel Pharmaceuticals made up 0.1% of Carmichael Hill & Associates's portfolio in Q3 2024, its #156 holding.
  • Carmichael Hill & Associates first reported a position in Avadel Pharmaceuticals in Q4 2019 and has held it in 20 quarters since.
  • Carmichael Hill & Associates's Avadel Pharmaceuticals position peaked at $355K in Q1 2024.
  • 176 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q3 2024.

Based on Carmichael Hill & Associates's 13F filing for Q3 2024, filed 29 Oct 2024.